Patients with advanced stage non-small cell lung cancer who have progressed after standard treatments are generally eligible for Lung MAP. Eligibility criteria may vary depending on the specific treatment arms available at any given time. It is crucial for patients to undergo genomic profiling to determine the specific genetic alterations in their tumors before they can be assigned to a treatment arm.
